Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen‐deprivation therapy for hormone‐naïve bone‐metastatic prostate cancer

Abstract

In a large cohort of Scandinavian men with hormone-naïve M1b prostate cancer, an increase in Hb concentration between baseline and 3 months of ADT was associated with significantly poorer survival, whereas an increase between 6 and 12 months was associated with better survival. These findings provide new information about patterns of change in Hb concentrations during 12 months of ADT for M1b prostate cancer, and survival. Clinicians should be aware of the prognostic value of Hb concentration changes during ADT in M1b prostate cancer.

Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy

“…Hemoglobin concentration (HGB) is a routinely measured blood parameter, and its prognostic value is well-recognized across various malignancies [ 8 , 9 ]. The prognostic value of HGB in metastatic prostate cancer has also been documented [ 10 , 11 , 12 ]. However, only few studies thus far have evaluated the ability of HGB to predict outcomes in localized PCa [ 13 , 14 ].Considering its value in predicting both disease-specific mortality [ 10 ] and all-cause mortality [ 15 , 16 ], HGB promises to be a valuable tool to predict the survival of PCa patients.…”

Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients undergoing Radiotherapy

“…Hemoglobin concentration (HGB) is a routinely measured blood parameter, and its prognostic value is well recognized across various malignancies [8,9]. Prognostic value of HGB in metastatic prostate cancer has been also documented [10][11][12]. However, few studies so far evaluated the ability of HGB to predict outcome in localized PCa [13,14].…”